Cyclacel Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1996-01-01

Employees: 12

Market Cap: -

Website: http://www.cyclacel.com

Introduction: Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Clinical Trials

Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects

Early Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: Fadraciclib

First Posted Date: 2023-04-18

Last Posted Date: 2024-02-07

Lead Sponsor: Cyclacel Pharmaceuticals, Inc.

Target Recruit Count: 8

Registration Number: NCT05817890

Locations: 🇺🇸
Labcorp Clinical Research Unit, Madison, Wisconsin, United States

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

Phase 1

Recruiting

Conditions: Solid Tumor, Adult Lymphoma

Interventions: Drug: CYC140

First Posted Date: 2022-05-03

Last Posted Date: 2024-02-07

Lead Sponsor: Cyclacel Pharmaceuticals, Inc.

Target Recruit Count: 330

Registration Number: NCT05358379

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

Phase 1

Suspended

Conditions: Myelodysplastic Syndrome(MDS)
Leukemia

Interventions: Drug: fadraciclib

First Posted Date: 2021-12-23

Last Posted Date: 2024-02-08

Lead Sponsor: Cyclacel Pharmaceuticals, Inc.

Target Recruit Count: 210

Registration Number: NCT05168904

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
City of Hope, Duarte, California, United States

A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

Phase 1

Recruiting

Conditions: Solid Tumor, Adult
Lymphoma

Interventions: Drug: Fadraciclib

First Posted Date: 2021-07-30

Last Posted Date: 2024-01-25

Lead Sponsor: Cyclacel Pharmaceuticals, Inc.

Target Recruit Count: 330

Registration Number: NCT04983810

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
City of Hope, Duarte, California, United States
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 1 locations

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Phase 1

Completed

Conditions: AML
MDS

Interventions: Drug: CYC065
Drug: Venetoclax

First Posted Date: 2019-07-12

Last Posted Date: 2024-01-25

Lead Sponsor: Cyclacel Pharmaceuticals, Inc.

Target Recruit Count: 14

Registration Number: NCT04017546

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Phase 1

Conditions: AML, Adult
Myelodysplastic Syndromes
CML, Refractory
CLL, Refractory
ALL, Adult

Interventions: Drug: CYC140

First Posted Date: 2019-03-21

Last Posted Date: 2022-04-25

Lead Sponsor: Cyclacel Pharmaceuticals, Inc.

Target Recruit Count: 50

Registration Number: NCT03884829

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

Phase 1

Completed

Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: CYC065
Drug: Venetoclax

First Posted Date: 2018-11-14

Last Posted Date: 2024-01-25

Lead Sponsor: Cyclacel Pharmaceuticals, Inc.

Target Recruit Count: 5

Registration Number: NCT03739554

Locations: 🇺🇸
Investigational Site, Houston, Texas, United States

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: CYC065

First Posted Date: 2015-09-17

Last Posted Date: 2024-05-31

Lead Sponsor: Cyclacel Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT02552953

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Sapacitabine
Drug: Decitabine

First Posted Date: 2011-02-25

Last Posted Date: 2022-06-22

Lead Sponsor: Cyclacel Pharmaceuticals, Inc.

Target Recruit Count: 482

Registration Number: NCT01303796

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
St. Francis Medical Group Oncology and Hematology Specialists, Indianapolis, Indiana, United States

and more 114 locations

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Phase 1

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: sapacitabine and venetoclax (Part 2 - recruiting)
Drug: sapacitabine and decitabine (Part 1 - completed)

First Posted Date: 2010-09-29

Last Posted Date: 2019-07-16

Lead Sponsor: Cyclacel Pharmaceuticals, Inc.

Target Recruit Count: 65

Registration Number: NCT01211457

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy